[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500017":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":19,"locations":27,"responsibleParty":47,"collaborators":50,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of British Columbia","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Children with Type 1 diabetes",null,"children recruited within 14 weeks of type 1 diabetes diagnosis and followed for 24 months.",[13,17],{"name":14,"affiliation":15,"role":16},"Angela Devlin, PhD","UBC Pediatrics\u002FBC Children's Hospital Research Institute","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":15,"role":16},"Constadina Panagiotopoulos, MD",[20,25],{"name":14,"role":21,"phone":22,"phoneExt":23,"email":24},"CONTACT","6048752000","5378","adevlin@bcchr.ubc.ca",{"name":18,"role":21,"phone":10,"phoneExt":10,"email":26},"dpanagiotopoulos@cw.bc.ca",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Endocrine and Diabetes Unit, BC Children's Hospital","RECRUITING","Vancouver","British Columbia","V5Z4H4","Canada","CA",{"type":37,"coordinates":38},"Point",[39,40],-123.11934,49.24966,{"lat":40,"lon":39},[43],{"name":44,"role":21,"phone":22,"phoneExt":45,"email":46},"Gemma Anderson","4695","gemma.anderson@cw.bc.ca",{"type":16,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Angela Devlin","Professor of Pediatrics",[51,54],{"name":52,"class":53},"Canadian Institutes of Health Research (CIHR)","OTHER_GOV",{"name":55,"class":6},"BC Children's Hospital Research Institute","100500017","vascular-complications-in-children-from-t1d-diagnosis-100500017",false,"NCT05790785","Vascular Complications in Children From T1D Diagnosis","Understanding Vascular Complications in Children From Type 1 Diabetes Diagnosis","Inclusion Criteria\n\n1. Between the ages of 8-18 years\n2. Within 14 weeks of type 1 diabetes diagnosis\n3. Ability and willingness to undergo non-invasive arterial stiffness assessment for 1hr and willingness to wear the 24-h automated blood pressure monitoring (ABPM) device.\n\nExclusion Criteria\n\nChildren will be ineligible to participate in the study if they meet any of the following:\n\n1. Other cardiometabolic or endocrine diseases diagnosis (type 2 diabetes; familial disorders of cholesterol metabolism; lupus)\n2. Other genetic syndromes (Down Syndrome; Prader-Willi)\n3. Eating disorder diagnosis\n4. Transgender children taking hormone blockers or exogenous sex steroids\n5. Currently treated with medications known to affect metabolism (e.g. glucocorticoids, antipsychotics).","ALL","8 Years","18 Years",{"count":67,"type":68},150,"ESTIMATED","OBSERVATIONAL","Cardiovascular disease is a complication of type 1 diabetes (T1D), a life-long disease, usually diagnosed in childhood. The goal of this project is to determine the timing and factors leading to vascular damage in children from T1D diagnosis.",[72,73,74,75],"Type 1 Diabetes","Cardiovascular Complications","Child","Adolescent",[77,78,79,80,81,82,83],"Type 1 diabetes","Children","Arterial stiffness","Body composition","Biomarkers","Nutrition","Blood pressure","2025-04-29",{"date":86,"type":87},"2025-05-02","ACTUAL",{"date":89,"type":87},"2024-03-25",{"date":91,"type":68},"2027-09-30",{"name":5,"class":6},1]